TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), is pleased to advise its shareholders that in accordance with its previously announced strategy of diversifying its product portfolio, in order to reduce its exposure to the strictly regulated environment of Cannabis-based products, it has launched the formulation and production of a full line of botanical-derived food supplements, through its subsidiary Hempoland Sp Zoo (“Hempoland”) under its Marishanti brand.
The Company expresses its recognition and thanks to the R&D, Quality and Production teams of Hempoland for their commitment and ongoing professional excellence.
Hempoland has successfully filed notification to the Competent Regulatory Authority for the first phase of its health supportive portfolio and has commenced sales in the EU with a view to international expansion including its online presence.
The product line available by April 30th, 2024, includes and will include:
-
Hypericum Perforatum
(“St. John’s Wort”)
-
Valeriana Officinalis L.
(“Valerian Root”)
-
Calendula Officinalis L.
(“Marigold Flower”)
-
Salvia Officinalis L.
(“Sage Leaf”)
-
Taraxacum Officinale F.H. Wigg
(“Dandelion Root”)
-
Crataegus spp
(“Hawthorn”)
-
Melissa Officinalis L.
(“Melissa Leaf”)
-
Ribes Nigrum L.
(“Blackcurrant”)
The beneficial properties of the above have been extensively tested and documented in numerous academic reviews and research papers.
Valeriana Officinalis L. (Valerian Root)
Additional SKUs, including non-restrictive functional mushroom, are under current development and Management expects to commence sales in 3Q2024.
The use of plant extracts is experiencing strong growth in the global market as consumers seek out natural and healthy products with beneficial properties. The urban population, with evolving lifestyles, has become increasingly health-conscious resulting in wider acceptance of alternative natural products fuelling the growth of botanical-derived food supplements. The global plant-extract market was estimated at USD 34.4 billion in 2022 and it is projected to grow at a CAGR of 12.3% to reach USD 61.5 billion by 2027 (source: www.marketsandmarkets.com).
About RAMM Pharma Corp. RAMM Pharma is a leader in the field of cannabinoid pharmacology and product formulation for cannabis- based pharmaceuticals and other hemp-based products with a unique and diversified international production and sales platform. The Company operates an established pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant -derived cannabinoid pharmaceutical products that have been authorized for sale and/or compassionate use in several Latin American countries. RAMM also has a pipeline of new products, including registered hemp- based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at the company's state-of-the-art, good-manufacturing-practice-certified formulation facility in Montevideo, Uruguay and Elblag, Poland.
In Europe, RAMM's vertically integrated operations are based in Ragusa, Italy and Elbląg, Poland (60 kilometres east of Gdańsk), and include large extraction and processing facilities. RAMM Pharma includes wholly owned subsidiaries Canapar Corp., HemPoland S.p.a. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forwardlooking statements") within the meaning of the applicable Canadian securities legislation. All statements, other thanstatements ofhistoricalfact,areforward-lookingstatementsandarebasedonexpectations,estimatesandprojectionsas at the date of this news release. Any statement that involves discussions with respect to predictions, expectations,beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrasessuch as “expects”, or “does not expect”, “isexpected”, “anticipates” or “does not anticipate”, “plans”, “budget”,“scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating thatcertain actions, events or results “may” or “could”, “would”, “might” or “wi ll” be taken to occur or be achieved) are notstatements of historical fact and may be forward-looking statements. In this news release, forward looking statementsrelate,amongotherthings,the Company’sstrategiesandobjectives,andfuture expansionplans.
These forward-looking statements are based on reasonable assumptions and estimatesof management of theCompany at the time such statements were made. Actual future results may differ materially as forward -lookingstatements involve known and unknown risks, uncertainties and other factors which may cause the actual results,performanceorachievementsoftheCompanytomateriallydifferfromanyfutureresults,performanceorachievementsexpressed or implied by such forward-looking statements. Such factors, among other things, include: future growthpotential of theCompany; fluctuations ingeneralmacroeconomic conditions; fluctuations insecuritiesmarkets;expectationsregardingthesizeoftheUruguayan,LatinAmerican,Europeanandinternationalmedicalandrecreationalcannabis markets and changing consumer habits; the ability of the Company to successfully achieve its businessobjectives; plans for expansion; political and social uncertainties; inability to obtain adequate insu rance to cover risksand hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production,distribution and sale of cannabis and cannabis related products in Uruguay or internationally; and employee relations.Although the forward-looking statements contained in this news release are based upon what management of theCompany believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholdersthat actual results will be consistent with such forward -looking statements, as there may be other factors that causeresultsnottobeasanticipated,estimatedorintended.Readersshouldnotplaceunduerelianceontheforward-lookingstatementsandinformationcontainedinthisnewsrelease.TheCompanyassumesnoobligationtoupdatetheforward-lookingstatementsofbeliefs,opinions,projections,orotherfactors,shouldtheychange,exceptasrequiredbylaw.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the informationcontainedherein.
